Skip to main content
IDNA logo
IDNA
(NYSEARCA)
iShares Genomics Immunology and Healthcare ETF
$39.23-- (--)
Loading... - Market loading

IDNA ETF: iShares Genomics Immunology and Healthcare ETF - Price, Holdings & Analysis

iShares Genomics Immunology and Healthcare ETF Price Chart

Price Chart

Loading chart...

Financial Metrics & Key Statistics

Fund characteristics, expense ratio, dividend yield, and performance metrics

Day's Range$38.88 - $39.57
52-Week High$41.49
52-Week Low$22.33
Open$39.46
Volume143.20K
Average Volume (3M)88.99K
Assets (AUM)190.00M
Expense Ratio0.47%
Total Holdings62
Inception DateJun 11, 2019
1 Day Change-1.36%
1 Month Change12.79%
6 Month Change29.73%
YTD Change49.62%
1 Year Change72.44%
52-Week Change71.98%
5 Year Change-27.98%
50-Day MA$35.42
200-Day MA$30.52
RSI58.79
Stochastic %K28.03
Stochastic %D59.83
Annual Dividend$0.43
Dividend Yield1.10%
Last Dividend Ex-DateDec 19, 2026
Dividend Growth YoY64.02%
Years Dividend Growth1

Frequently Asked Questions About iShares Genomics Immunology and Healthcare ETF

What is the current price of IDNA?

The latest IDNA price is $39.23. The 52-week range is $22.33–$41.49. IDNA has returned 72.0% over the past 52 weeks.

What is the expense ratio for IDNA?

IDNA's annual expense ratio is 0.47%. This represents the yearly cost of holding the fund, deducted from total returns. Compare with similar Equity ETFs in the ETF Screener.

Does IDNA pay dividends?

Yes, IDNA pays a 1.10% dividend yield. The last ex-dividend date was 2026-12-19. View full dividend history in the Dividends section.

What are the top holdings of IDNA?

IDNA's largest holdings are Moderna, Inc (5.9%), Twist Bioscience Corporation (4.9%), Bayer Aktiengesellschaft (4.7%) (combined weight: 15.5%). The fund holds 62 total positions. View the complete portfolio breakdown in the Holdings section.

How does IDNA compare to similar ETFs?

Compare IDNA (0.47% expense ratio, $190M AUM) against similar Equity ETFs using the ETF Screener. Filter by expense ratio, dividend yield, and performance to find alternatives.